Close Menu

NEW YORK (GenomeWeb) – Fluidigm reported after the close of the market on Thursday that its first quarter revenues grew 19 percent year over year on strong demand for the company's Helios and Hyperion imaging mass cytometry systems.

For the three months ended March 31, 2019, Fluidigm tallied $30.1 million in revenues, up from $25.3 million a year ago and besting analysts' consensus estimate of $29.2 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.